EA019202B1 - Способ проведения аллерген-специфической иммунотерапии для профилактики или лечения аллергии - Google Patents
Способ проведения аллерген-специфической иммунотерапии для профилактики или лечения аллергии Download PDFInfo
- Publication number
- EA019202B1 EA019202B1 EA201071182A EA201071182A EA019202B1 EA 019202 B1 EA019202 B1 EA 019202B1 EA 201071182 A EA201071182 A EA 201071182A EA 201071182 A EA201071182 A EA 201071182A EA 019202 B1 EA019202 B1 EA 019202B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- allergen
- administration
- season
- seasonal
- weeks
- Prior art date
Links
- 239000013566 allergen Substances 0.000 title claims abstract description 158
- 206010020751 Hypersensitivity Diseases 0.000 title claims abstract description 44
- 238000009169 immunotherapy Methods 0.000 title claims abstract description 36
- 230000007815 allergy Effects 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims abstract description 25
- 208000026935 allergic disease Diseases 0.000 title abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 48
- 230000001932 seasonal effect Effects 0.000 claims abstract description 33
- 239000007909 solid dosage form Substances 0.000 claims abstract description 19
- 238000011282 treatment Methods 0.000 claims description 70
- 230000002009 allergenic effect Effects 0.000 claims description 45
- 241000196324 Embryophyta Species 0.000 claims description 42
- 229940074608 allergen extract Drugs 0.000 claims description 13
- 239000002552 dosage form Substances 0.000 claims description 13
- 239000003826 tablet Substances 0.000 claims description 13
- 239000013573 pollen allergen Substances 0.000 claims description 12
- 230000002538 fungal effect Effects 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000007891 compressed tablet Substances 0.000 claims description 3
- 239000013574 grass pollen allergen Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 229940046536 tree pollen allergenic extract Drugs 0.000 claims description 3
- 230000008520 organization Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract description 8
- 150000003839 salts Chemical class 0.000 description 36
- 229960004784 allergens Drugs 0.000 description 35
- 210000004400 mucous membrane Anatomy 0.000 description 35
- 239000000284 extract Substances 0.000 description 30
- 229910052751 metal Inorganic materials 0.000 description 27
- 239000002184 metal Substances 0.000 description 27
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 25
- 229910052760 oxygen Inorganic materials 0.000 description 25
- 239000001301 oxygen Substances 0.000 description 25
- 238000012360 testing method Methods 0.000 description 25
- 210000000214 mouth Anatomy 0.000 description 24
- 208000024891 symptom Diseases 0.000 description 21
- 230000004071 biological effect Effects 0.000 description 20
- 230000000694 effects Effects 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 14
- 239000000902 placebo Substances 0.000 description 13
- 229940068196 placebo Drugs 0.000 description 13
- 229960005486 vaccine Drugs 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 206010067484 Adverse reaction Diseases 0.000 description 10
- 230000006838 adverse reaction Effects 0.000 description 10
- 206010010741 Conjunctivitis Diseases 0.000 description 9
- 238000012423 maintenance Methods 0.000 description 9
- 239000008859 Grazax Substances 0.000 description 8
- 208000006673 asthma Diseases 0.000 description 8
- 230000000977 initiatory effect Effects 0.000 description 8
- 238000001179 sorption measurement Methods 0.000 description 8
- 239000008297 liquid dosage form Substances 0.000 description 7
- 230000003285 pharmacodynamic effect Effects 0.000 description 7
- 210000003800 pharynx Anatomy 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 6
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000007613 environmental effect Effects 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 208000003251 Pruritus Diseases 0.000 description 5
- 239000013572 airborne allergen Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000007803 itching Effects 0.000 description 5
- 102000009016 Cholera Toxin Human genes 0.000 description 4
- 108010049048 Cholera Toxin Proteins 0.000 description 4
- 230000000172 allergic effect Effects 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- -1 for example Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000010152 pollination Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 241000233866 Fungi Species 0.000 description 3
- 206010024769 Local reaction Diseases 0.000 description 3
- 208000030961 allergic reaction Diseases 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000009101 premedication Methods 0.000 description 3
- 206010039083 rhinitis Diseases 0.000 description 3
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- HDYRYUINDGQKMC-UHFFFAOYSA-M acetyloxyaluminum;dihydrate Chemical compound O.O.CC(=O)O[Al] HDYRYUINDGQKMC-UHFFFAOYSA-M 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 2
- 229940009827 aluminum acetate Drugs 0.000 description 2
- 150000001449 anionic compounds Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- GUPPESBEIQALOS-UHFFFAOYSA-L calcium tartrate Chemical compound [Ca+2].[O-]C(=O)C(O)C(O)C([O-])=O GUPPESBEIQALOS-UHFFFAOYSA-L 0.000 description 2
- 239000001427 calcium tartrate Substances 0.000 description 2
- 235000011035 calcium tartrate Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000000760 immunoelectrophoresis Methods 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 229910001412 inorganic anion Inorganic materials 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000001370 mediastinum Anatomy 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 150000002891 organic anions Chemical class 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000011425 standardization method Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 238000002636 symptomatic treatment Methods 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 2
- 229960001763 zinc sulfate Drugs 0.000 description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 description 2
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 239000010267 Allergoid Substances 0.000 description 1
- 241000208841 Ambrosia trifida Species 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 241000219495 Betulaceae Species 0.000 description 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 241000726768 Carpinus Species 0.000 description 1
- 235000001543 Corylus americana Nutrition 0.000 description 1
- 240000007582 Corylus avellana Species 0.000 description 1
- 235000007466 Corylus avellana Nutrition 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 240000005109 Cryptomeria japonica Species 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068355 Oral allergy syndrome Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 244000268528 Platanus occidentalis Species 0.000 description 1
- 235000006485 Platanus occidentalis Nutrition 0.000 description 1
- 241000209048 Poa Species 0.000 description 1
- 241000209049 Poa pratensis Species 0.000 description 1
- 206010057765 Procedural complication Diseases 0.000 description 1
- 241000238711 Pyroglyphidae Species 0.000 description 1
- 244000305267 Quercus macrolepis Species 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 206010043521 Throat irritation Diseases 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- SXQXMCWCWVCFPC-UHFFFAOYSA-N aluminum;potassium;dioxido(oxo)silane Chemical compound [Al+3].[K+].[O-][Si]([O-])=O.[O-][Si]([O-])=O SXQXMCWCWVCFPC-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 229940092690 barium sulfate Drugs 0.000 description 1
- 229910052790 beryllium Inorganic materials 0.000 description 1
- WPJWIROQQFWMMK-UHFFFAOYSA-L beryllium dihydroxide Chemical compound [Be+2].[OH-].[OH-] WPJWIROQQFWMMK-UHFFFAOYSA-L 0.000 description 1
- 229910001865 beryllium hydroxide Inorganic materials 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-M bromate Chemical class [O-]Br(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-M 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940046533 house dust mites Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-N iodic acid Chemical class OI(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-N 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940099076 maalox Drugs 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 201000004338 pollen allergy Diseases 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 229940043825 zinc carbonate Drugs 0.000 description 1
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 1
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 1
- 229940007718 zinc hydroxide Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4440108P | 2008-04-11 | 2008-04-11 | |
| DKPA200800533 | 2008-04-11 | ||
| PCT/EP2009/054186 WO2009124954A1 (en) | 2008-04-11 | 2009-04-08 | Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201071182A1 EA201071182A1 (ru) | 2011-06-30 |
| EA019202B1 true EA019202B1 (ru) | 2014-01-30 |
Family
ID=39809974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201071182A EA019202B1 (ru) | 2008-04-11 | 2009-04-08 | Способ проведения аллерген-специфической иммунотерапии для профилактики или лечения аллергии |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9248097B2 (https=) |
| EP (1) | EP2265285B1 (https=) |
| JP (2) | JP5618981B2 (https=) |
| CN (1) | CN102014954A (https=) |
| AU (1) | AU2009235490B2 (https=) |
| BR (1) | BRPI0911433A2 (https=) |
| CA (1) | CA2720455A1 (https=) |
| DE (1) | DE202008006598U1 (https=) |
| EA (1) | EA019202B1 (https=) |
| ES (1) | ES2406391T3 (https=) |
| MX (1) | MX2010011012A (https=) |
| WO (1) | WO2009124954A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05005528A (es) * | 2002-11-26 | 2006-04-05 | Alk Abello As | Producto farmaceutico de alergeno. |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| DE202008006598U1 (de) * | 2008-04-11 | 2008-10-02 | Alk-Abelló A/S | Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung |
| KR20130118884A (ko) | 2010-10-15 | 2013-10-30 | 알크-아벨로 에이/에스 | 알레르겐 소스 물질로부터 유도된 무관련 알레르겐을 이용한 과민성 면역반응의 억제 |
| US20120100163A1 (en) * | 2010-10-15 | 2012-04-26 | Alk-Abello A/S | Suppression of a type 1 hypersensitivity immune response with an unrelated antigen |
| WO2012148549A1 (en) | 2011-02-25 | 2012-11-01 | Benaroya Research Institute | Detection of an immune response |
| JP2012240978A (ja) * | 2011-05-20 | 2012-12-10 | Nitto Denko Corp | 医薬組成物及びゼリー状製剤 |
| JP2012240975A (ja) * | 2011-05-20 | 2012-12-10 | Nitto Denko Corp | 医薬組成物及びゼリー状製剤 |
| SG11201402650RA (en) | 2012-01-16 | 2014-06-27 | Elizabeth Mckenna | Compositions and methods for the treatment of hepatic diseases and disorders |
| US12268718B2 (en) | 2012-01-16 | 2025-04-08 | Labyrinth Holdings Llc | Control of cellular redox levels |
| JP6306588B2 (ja) | 2012-08-21 | 2018-04-04 | サノフィ・バイオテクノロジー | Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法 |
| PL2892927T3 (pl) | 2012-09-07 | 2018-11-30 | Regeneron Pharmaceuticals, Inc. | Sposoby leczenia atopowego zapalenia skóry przez podawanie antagonisty IL-4R |
| BR112015006264A2 (pt) | 2012-09-21 | 2017-07-04 | Mckenna Elizabeth | composições de oligonucleotídeos cpg ocorrendo naturalmente e suas aplicações terapêuticas |
| TWI755763B (zh) | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
| TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| KR102695088B1 (ko) | 2014-02-28 | 2024-08-16 | 리제너론 파아마슈티컬스, 인크. | Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법 |
| CA3246946A1 (en) | 2014-11-14 | 2025-11-29 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
| ES2994774T3 (en) | 2016-09-01 | 2025-01-31 | Regeneron Pharma | Methods for preventing or treating allergy by administering an il-4r antagonist |
| WO2018057776A1 (en) | 2016-09-22 | 2018-03-29 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an il-4r inhibitor |
| TWI857389B (zh) | 2016-12-01 | 2024-10-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| US11053309B2 (en) | 2017-08-04 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
| KR102694419B1 (ko) | 2017-10-30 | 2024-08-09 | 사노피 바이오테크놀로지 | Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법 |
| BR112020020387A2 (pt) | 2018-05-13 | 2021-01-19 | Regeneron Pharmaceuticals, Inc. | Métodos para o tratamento de dermatite atópica por administração de um inibidor de il-4r |
| CN113597328B (zh) | 2019-03-21 | 2025-10-31 | 瑞泽恩制药公司 | 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合 |
| WO2021011614A1 (en) | 2019-07-16 | 2021-01-21 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
| JP7836754B2 (ja) | 2019-08-05 | 2026-03-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｉｌ－４ｒアンタゴニストを投与することによりアレルギーを治療しアレルゲン特異的免疫療法を増強するための方法 |
| CN114173816A (zh) | 2019-08-05 | 2022-03-11 | 瑞泽恩制药公司 | 通过施用il-4r拮抗剂治疗特应性皮炎的方法 |
| EP4513185A1 (en) * | 2023-08-22 | 2025-02-26 | Luxembourg Institute of Health (LIH) | Early response biomarkers for allergen immunotherapy |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005083385A2 (en) * | 2004-02-26 | 2005-09-09 | Alk-Abelló A/S | Method of evaluating the therapeutic potential of a vaccine for mucosal administration |
| WO2007051476A1 (en) * | 2005-11-04 | 2007-05-10 | Alk-Abelló A/S | Use of a liquid allergy vaccine formulation for oromucosal administration |
| DE202007004567U1 (de) * | 2007-03-28 | 2007-10-11 | Alk-Abelló A/S | Verwendung einer adjuvierten Allergievakzinformulierung zur parenteralen Verabreichung |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK137992D0 (da) | 1992-11-13 | 1992-11-13 | Alk Lab As | Fremgangsmaade til paavisning af et immunologisk aktivt stof i en proeve under anvendelse af et maerkningsstof |
| JPH0959179A (ja) * | 1995-08-28 | 1997-03-04 | Japan Tobacco Inc | スギ花粉症予防性を有する口腔衛生剤 |
| DK1062341T3 (da) | 1998-03-16 | 2008-11-03 | Alk Abello As | Muterede rekombinante allergener |
| FR2778244B1 (fr) | 1998-04-30 | 2000-07-13 | Univ Joseph Fourier | Procede d'excitation d'une cavite optique pour la detection de gaz a l'etat de traces |
| CN100577804C (zh) | 2000-11-16 | 2010-01-06 | 阿尔克-阿贝洛有限公司 | 新型变态反应原突变体 |
| CN1668737A (zh) | 2002-05-16 | 2005-09-14 | 阿尔克-阿贝洛有限公司 | 重组Bet.V.1过敏原突变体及其方法和制备 |
| MXPA05005528A (es) * | 2002-11-26 | 2006-04-05 | Alk Abello As | Producto farmaceutico de alergeno. |
| US8491909B2 (en) | 2004-02-06 | 2013-07-23 | Greer Laboratories, Inc. | Methods and compositions for dosing of allergens |
| US20060115499A1 (en) | 2004-09-27 | 2006-06-01 | Alk-Abello A/S | Liquid allergy vaccine formulation for oromucosal administration |
| WO2006050729A2 (en) | 2004-11-10 | 2006-05-18 | Alk-Abellò A/S | Method of preventive treatment of allergy by mucosal administration of an allergy vaccine |
| PT1812059E (pt) * | 2004-11-10 | 2010-07-26 | Alk Abelle As | MéTODO DE TRATAMENTO PREVENTIVO DA ALERGIA POR ADMINISTRAÆO POR VIA MUCOSAL DE UMA VACINA PARA A ALERGIA |
| CN101098711A (zh) * | 2005-01-07 | 2008-01-02 | 阿尔克-阿贝洛有限公司 | 通过口粘膜施用变态反应疫苗预防性治疗变态反应的方法 |
| US20060210590A1 (en) * | 2005-02-03 | 2006-09-21 | Alk-Abello A/S | Minor allergen control to increase safety of immunotherapy |
| EP1933867A1 (en) | 2005-10-04 | 2008-06-25 | Alk-Abello A/S | Solid vaccine formulation |
| EP1974746B1 (en) * | 2007-03-28 | 2012-01-11 | Alk-Abelló A/S | Use of an adjuvanted allergy vaccine formulation for parenteral administration |
| DE202008006598U1 (de) * | 2008-04-11 | 2008-10-02 | Alk-Abelló A/S | Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung |
-
2008
- 2008-05-15 DE DE202008006598U patent/DE202008006598U1/de not_active Expired - Lifetime
-
2009
- 2009-04-08 EP EP09730293A patent/EP2265285B1/en not_active Revoked
- 2009-04-08 JP JP2011503429A patent/JP5618981B2/ja not_active Expired - Fee Related
- 2009-04-08 AU AU2009235490A patent/AU2009235490B2/en not_active Ceased
- 2009-04-08 EA EA201071182A patent/EA019202B1/ru not_active IP Right Cessation
- 2009-04-08 CA CA2720455A patent/CA2720455A1/en not_active Abandoned
- 2009-04-08 CN CN2009801154343A patent/CN102014954A/zh active Pending
- 2009-04-08 MX MX2010011012A patent/MX2010011012A/es active IP Right Grant
- 2009-04-08 ES ES09730293T patent/ES2406391T3/es active Active
- 2009-04-08 BR BRPI0911433A patent/BRPI0911433A2/pt not_active IP Right Cessation
- 2009-04-08 US US12/988,513 patent/US9248097B2/en active Active
- 2009-04-08 WO PCT/EP2009/054186 patent/WO2009124954A1/en not_active Ceased
-
2014
- 2014-01-10 US US14/152,753 patent/US20140127298A1/en not_active Abandoned
- 2014-09-16 JP JP2014187908A patent/JP2015013891A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005083385A2 (en) * | 2004-02-26 | 2005-09-09 | Alk-Abelló A/S | Method of evaluating the therapeutic potential of a vaccine for mucosal administration |
| WO2007051476A1 (en) * | 2005-11-04 | 2007-05-10 | Alk-Abelló A/S | Use of a liquid allergy vaccine formulation for oromucosal administration |
| DE202007004567U1 (de) * | 2007-03-28 | 2007-10-11 | Alk-Abelló A/S | Verwendung einer adjuvierten Allergievakzinformulierung zur parenteralen Verabreichung |
Non-Patent Citations (9)
| Title |
|---|
| DAHL RONALD ET AL.: "Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years" JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 121, no. 2, February 2008 (2008-02), pages 512-518, XP002505159 ISSN: 0091-6749 the whole document * |
| FRATI FRANCO ET AL.: "Mucosal immunization application to allergic disease: sublingual immunotherapy." ALLERGY AND ASTHMA PROCEEDINGS : THE OFFICIAL JOURNAL OF REGIONAL AND STATE ALLERGY SOCIETIES 2007 JAN-FEB, vol. 28, no. 1, January 2007 (2007-01), pages 35-39, XP009109006 ISSN: 1088-5412 * |
| KLEINE-TEBBE J. ET AL.: "Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial" ALLERGY, MUNSKGAARD, COPENHAGEN, vol. 61, no. 2, 1 February 2006 (2006-02-01), pages 181-184, XP002392406 ISSN: 0105-4538 * |
| KOPP М.V. ЕТ AL.: "Administration schedules of specific immunotherapy" ALLER60 JOURNAL 200712 DE, vol. 16, no. 8, December 2007 (2007-12), pages 570-575, XP009108997 ISSN: 0941-8849 page 574, left-hand column - page 575; table 2 * |
| NIGGEMANN В. ET AL.: "Five-year follow-up on the PAT study: specific Immunotherapy and long-term prevention of asthma in children" ALLERGY, MUNSKGAARD, COPENHAGEN, vol. 61, no. 7, 1 July 2006 (2006-07-01), pages 855-859, XP002437350 ISSN: 0105-4538 * |
| NOVEMBRE E. ET AL.: "Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis" JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY - YEARLY BOOK, INC, US, vol. 114, no. 4, 1 October 2004 (2004-10-01), pages 851-857, XP004631432 ISSN: 0091-6749 the whole document * |
| ON BEHALF OF THE UK IMMUNOTHERAPY STUDY GROUP FREW ET AL.: "Efficacy and safety of specific Immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis" JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY - YEARLY BOOK, INC, US, vol. 117, no. 2, 1 February 2006 (2006-02-01), pages 319-325, XP005275416 ISSN: 0091-6749 * |
| OTT H. ET AL.: "ECRIT-study: efficacy and safety of coseasonal SLIT in patients with grass pollen allergy over a 3 years period" ALLERGY (OXFORD), vol. 62, no. Suppl. 83, June 2007 (2007-06), page 72, XP002505158 & 26TH CONGRESS OF THE EUROPEAN-ACADEMY-OF-ALLERGOLOGY-AND-CLINIC AL-IMM UNOLOGY; GOTEBORG, SWEDEN; JUNE 09-13, 2007 ISSN: 0105-4538 abstract * |
| SEIDENBERG J. ET AL.: "EVALUATION OF THE SAFETY OF A SEASONAL ULTRA RUSH HIGH-DOSE SUBLINGUAL IMMUNOTHERAPY IN CHILDREN WITH ALLERGIC RHINITIS TO TREE POLLEN AND GRASS POLLEN" CLINICAL AND EXPERIMENTAL ALLERGY, BLACKWELL SCIENTIFIC PUBLICATIONS, LONDON, GB, vol. 36, no. 9, 1 September 2006 (2006-09-01), pages 1205-1206, XP009085031 ISSN: 0954-7894 cited in the application abstract * |
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0911433A2 (pt) | 2016-07-26 |
| CN102014954A (zh) | 2011-04-13 |
| US20110142934A1 (en) | 2011-06-16 |
| EP2265285B1 (en) | 2013-03-20 |
| JP5618981B2 (ja) | 2014-11-05 |
| WO2009124954A1 (en) | 2009-10-15 |
| HK1147946A1 (en) | 2011-08-26 |
| CA2720455A1 (en) | 2009-10-15 |
| AU2009235490A1 (en) | 2009-10-15 |
| EP2265285A1 (en) | 2010-12-29 |
| AU2009235490B2 (en) | 2013-10-24 |
| MX2010011012A (es) | 2010-11-12 |
| US20140127298A1 (en) | 2014-05-08 |
| DE202008006598U1 (de) | 2008-10-02 |
| JP2011516521A (ja) | 2011-05-26 |
| JP2015013891A (ja) | 2015-01-22 |
| EA201071182A1 (ru) | 2011-06-30 |
| US9248097B2 (en) | 2016-02-02 |
| ES2406391T3 (es) | 2013-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA019202B1 (ru) | Способ проведения аллерген-специфической иммунотерапии для профилактики или лечения аллергии | |
| JP5442924B2 (ja) | アレルゲン剤形 | |
| HK1200019A1 (en) | Use of a liquid allergy vaccine formulation for oromucosal administration | |
| Ebner et al. | Booster immunotherapy (BIT) | |
| MX2011003752A (es) | Producto farmaceutico para dosificacion ascendente de vacuna contra alergia. | |
| Parra et al. | Ultrafast regimen for Pru p3 sublingual immunotherapy (SLIT-Peach®) in patients with anaphylactic LTP-Syndrome | |
| EP1974746B1 (en) | Use of an adjuvanted allergy vaccine formulation for parenteral administration | |
| EP2167084B1 (en) | An allergen dosage form comprising an antihistamine | |
| ES2380172T3 (es) | Uso de una formulación de vacuna de la alergia coadyuvada para administración parenteral | |
| HK1147946B (en) | Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season | |
| CN101340892A (zh) | 用于口腔粘膜给药的液体变态反应性疫苗制剂的用途 | |
| CN103933562A (zh) | 用于口腔粘膜给药的液体变态反应性疫苗制剂的用途 | |
| HK1110773B (en) | Use of a liquid allergy vaccine formulation for oromucosal administration | |
| JP2016535793A (ja) | 口腔アレルギー症候群の予防および治療のための製剤および方法 | |
| HK1124790B (en) | Use of an adjuvanted allergy vaccine formulation for parenteral administration | |
| HK1087008B (en) | An allergen dosage form | |
| HK1147215A (en) | An allergen dosage form |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AZ BY KZ KG MD TJ |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): TM |